CN114306543A - Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof Download PDFInfo
- Publication number
- CN114306543A CN114306543A CN202210042538.3A CN202210042538A CN114306543A CN 114306543 A CN114306543 A CN 114306543A CN 202210042538 A CN202210042538 A CN 202210042538A CN 114306543 A CN114306543 A CN 114306543A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- beta
- chinese medicine
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating Alzheimer disease and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-15 parts of eclipta prostrata, 3-8 parts of artemisia anomala, 2-6 parts of alpinia katsumadai, 5-15 parts of cluster mallow seeds, 2-6 parts of cortex periplocae and 10-15 parts of fiveleaf akebia fruit. The Chinese medicinal composition has the basic effects of invigorating kidney, removing blood stasis, invigorating stomach, moisturizing intestine, eliminating dampness and regulating qi-flowing. Animal experiment results show that the high dose (12.74g/kg) and the medium dose (6.37g/kg) of the traditional Chinese medicine composition can improve the learning ability of Kunming mice with the Alzheimer disease induced by beta-amyloid, the expression level of beta-amyloid precursor protein, the expression level of interleukin-1 beta and the expression level of acetylcholine metabolic enzyme, and simultaneously have no influence on the main organ index and the body weight of the mice, which indicates that the traditional Chinese medicine composition is effective in treating the Alzheimer disease and has no side effect.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, a preparation method and application thereof, in particular to a traditional Chinese medicine composition for treating Alzheimer disease, and a preparation method and application thereof. The invention belongs to the technical field of traditional Chinese medicine research.
Background
Alzheimer's Disease is a common senile Disease (Hampel H, Vassar R, De Strooper B, et al. the beta-Secretase BACE1 in Alzheimer's Disease [ J ]. Biol Psychiatry, 2021, 89 (8): 745-756.) and is related to the increase in beta-amyloid content in different regions of brain tissue (Busche MA, Hyman BT. synergy Webet amyloid-beta and tau in Alzheimer's Disease [ J ]. Nat Neurosci, 2020, 23 (10): 1183-1193.). Beta-amyloid is a very powerful stimulator of Alzheimer's Disease (Chen WT, Lu A, Craessaerts K, et al. spatial transport and In Situ Sequencing to Study Alzheimer's Disease [ J ] Cell, 2020, 182 (4): 976:991.) and promotes the formation of positive feedback effect loop closely related to inflammatory response In the body brain tissue, and beta-amyloid content continues to increase (Breijyeh Z, Karaman R. comprehensive Review on Alzheimer's Disease diseases Causes and Treatment [ J ] Molecules, 2020, 25 (24): 5789.), and thus constantly aggravates the aseptic inflammatory response of brain tissue, which In turn Causes the corresponding symptoms and signs.
The data of the study show that Alzheimer's Disease is mostly accompanied by a decline in learning ability (Kent SA, Spires-joints TL, Durrant CS. the physical roles of tau and Abeta: experiments for Alzheimer's Disease pathfinding and therapeutics [ J ]. Acta Neuropathia, 2020, 140 (4): 417 amber 447.), that something that has recently happened is extremely easy to forget, that has a certain relation to an increase in the content of brain tissue inflammatory mediators and to damage to the hippocampus region, and that has a certain relation to an increase in the content of brain tissue beta-amyloid precursor protein, whereas an abnormal increase in brain tissue inflammatory mediators and their beta-amyloid precursor protein, and that a positive feedback increase in the content of beta-amyloid protein in regions different from brain tissue causes a decline in learning ability (Roussarie, Yao V, Rodriguez-Rodriguez P, Seuential virus J. [ basic J. ] growth of brain tissue, 2020, 107(5): 821-835) are closely related.
As the body ages, the production of free radicals in brain tissue gradually increases, and abnormal astrocyte structure causes abnormal blood brain barrier structure (Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer 'S disease activities in genetics and dietetic apoptosis [ J ]. Lancet Neurol, 2021, 20 (1): 68-80.), accompanied by abnormal choline system in brain tissue, abnormal content of acetylcholine metabolizing enzyme (Ren JM, Zhang SL, Wang XL, et al. expression level of the alpha7 organic cholesterol synthase of the branched tissue of the middle tissue and Alzheimer' S disease activities and of the tissue of the animal tissue of the formula SH-5, S.S. and E.E.J.: free radicals of the hormone synthesis of SH-5Y, J.21, Na J. (Na J.: 22. 12. D. 21. D. japonica, Na J.), 2021, 99(3): 750, 777), and further promote the waterfall type reaction of brain tissue free radicals, aggravate the inflammatory reaction of the organism.
In fact, the elderly and the infirm are often accompanied by emotional disturbances, pathological product accumulation is a relatively normal physiological phenomenon, and this is related to microglial activation (Bartels T, De Schepper S, Hong S. microglia modified neuro-genesis in Alzheimer ' S and Parkinson ' S diseases [ J ]. Science, 2020, 370 (6512): 66-69.), microglial activation causes an increase in interleukin-1. beta. content (Rahman MA, Islam K, Rahman S, et al. Neobiological Cross-talk Between COVID-19and Alzheimer ' S Disease [ J ]. Mol Neurobiosol, 2021, 58(3) 1017. quadrature 1023.) and promotes inflammatory response of brain tissue amyloid, and also promotes the gradual decomposition of beta-amyloid into beta-amyloid protein (JY T-amyloid J.) -precursor G, Wmmy protein, Wmmy. 3), 2020, 586(7831): 735 < J >. 740) for promoting the formation of a large number of senile plaques on the lateral side of neurons, inducing the aggravation of pathological changes of the brain tissue of the body, and promoting the increase of the content of acetylcholine in the brain tissue of the body, which is beneficial to Alzheimer's disease (Lanni C, Masi M, Racchi M, et al. cancer and Alzheimer's disease inducing and diagnosing an animal and a. J. Mol Psychiatry, 2021, 26 (1): 280-295.), to ameliorate beta-amyloid induced Alzheimer's disease, which requires a decrease in the level of acetylcholine metabolizing enzyme, and an increase in the level of choline acetylase.
It has been shown that lesions in Alzheimer's brain tissue are mainly concentrated in the hippocampal region (Richet K, Steullet P, Pachoud M, et al. tau administration in assays of the dendritic gyrus antigens with neurological function and memory deficits in Alzheimer's disease [ J ]. Nat Neurosci, 2020, 23 (12): 1567) 1579.). The hippocampal region can be generally divided into multiple neural divisions, with hippocampal 1 and hippocampal 3 regions being very closely related to Alzheimer's disease (Lyssenko NN, Pratico D.ABCA7 and the altered lipostasis hypothesis of Alzheimer's disease [ J ]. Alzheimer's details, 2021, 17 (2): 164-. The increase of free radical production and beta-amyloid content in hippocampal region (Ruan Z, Pathak D, Venkatesan Kalavai S, et al Alzheimer 'S disease both-derived extracellular vascular disease pathology in interneurons [ J ] Brain, 2021, 144 (1): 288 and 309), increase of interleukin-1 beta content, etc. can rapidly induce the body to have very obvious symptoms and signs, and many researchers mostly inject a large amount of beta-amyloid in hippocampal 1 region and hippocampal 3 region to establish a conventional Alzheimer' S disease model.
As is well known, many Drugs have a better effect on the induction of Alzheimer's disease by beta-amyloid, including anti-beta-amyloid Drugs (Lozupone M, Solfrizi V, DUrso F, et al. anti-amyloid-beta protein agents for the treatment of Alzheimer's disease: an upper on emitting Drugs [ J ]. Extra Optin Electron Drugs, 2020, 25 (3): 319-335), estrogens, vitamin B6, vitamin C (Yu JT, Xu W, Tan CC, et al. evaluation-based preservation of Alzheimer's disease, 1. fatty acid derivatives and method-analysis of amyloid's reaction, 1. resveratrol, 9. resveratrol, et al. 9. resveratrol, resveratrol-1. D. J. Alzhi et al nanosystems [ J ]. Drug Deliv, 2020, 27 (1): 502-518.), novel nano selenium and the like, but many drugs have certain side effects. In recent years, in order to overcome the side effects, many researchers select drugs with small side effects, overall regulatory function and relatively more targets to develop research on prevention and treatment of beta-amyloid induced alzheimer disease.
The traditional Chinese medicine theory considers that the Alzheimer disease is mostly deficient in origin and excessive in nature, and particularly, kidney qi deficiency (von Yijun, Zheng Wei, WangXingjia, and the like. research on the treatment of the Alzheimer type dementia by a kidney tonifying method advances [ J ]. Sichuan traditional Chinese medicine 2021, 39 (2): 214-217.), which has a certain relation with the age of the old. Sufficient kidney yang and strong learning ability can be realized when kidney qi is abundant, marrow sea vacuity is avoided, and the reduction of the learning ability of the old is relieved, so that the medicine with the function of tonifying the kidney is required to be selected for treating the Alzheimer disease. The digestion function of the diet of the old is often weak, so that nutrition and defense are disharmony, kidney essence is deficient, and the old is lack of nourishment (Chen Hui ze, talk to the world, Meng Sheng xi, research progress of preventing and treating the Alzheimer disease by combining traditional Chinese medicine and western medicine [ J ] the J.of cardiovascular and cerebrovascular diseases, 2021, 19 (12): 2025 + 2029.), and beta-amyloid is gradually deposited in brain tissues to aggravate the symptoms and physical signs of the organism, so the medicine with the functions of invigorating stomach and lubricating intestines is required to be selected for treating the Alzheimer disease. The theory and application of the shallow analysis method for preventing and treating senile dementia by ascending clear and descending turbid in light of the theory and application of the traditional Chinese medicine [ J ]. orbicular drug, 2021, 14 (2): 278 and 281.) promote the generation of free radicals in hippocampus area to be increased, the content of beta-amyloid protein to be increased, the content of interleukin-1 beta to be increased and the like to induce the Alzheimer disease. Therefore, the treatment of Alzheimer disease requires the functions of removing blood stasis and eliminating dampness. Comprehensive analysis shows that the treatment of the Alzheimer disease induced by the beta-amyloid needs to tonify kidney, remove blood stasis, invigorate stomach, moisten intestines, eliminate dampness and regulate qi.
Therefore, the invention provides a traditional Chinese medicine composition consisting of 6 traditional Chinese medicinal materials, which comprises 10-15 parts by weight of eclipta prostrata, 3-8 parts by weight of artemisia anomala, 2-6 parts by weight of katsumade galangal seed, 5-15 parts by weight of cluster mallow seed, 2-6 parts by weight of cortex periplocae and 10-15 parts by weight of fiveleaf akebia fruit. Animal experiment results show that the traditional Chinese medicine composition with high dose (12.74g/kg) and the traditional Chinese medicine composition with medium dose (6.37g/kg) can improve learning ability, beta-amyloid precursor protein expression level, interleukin-1 beta expression level and acetylcholine metabolic enzyme expression level of Kunming mice with beta-amyloid induced Alzheimer disease, and meanwhile, the traditional Chinese medicine composition has no influence on main organ indexes and body weight of Kunming mice with beta-amyloid induced Alzheimer disease, so that the traditional Chinese medicine composition can be used for treating Alzheimer disease and has no side effect.
Disclosure of Invention
The invention aims to solve the technical problem of providing a traditional Chinese medicine composition for preventing and treating Alzheimer disease and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical means:
the invention relates to a traditional Chinese medicine composition for treating Alzheimer disease, which is characterized by comprising the following raw materials in parts by weight: 10-15 parts of eclipta prostrata, 3-8 parts of artemisia anomala, 2-6 parts of alpinia katsumadai, 5-15 parts of cluster mallow seeds, 2-6 parts of cortex periplocae and 10-15 parts of fiveleaf akebia fruit.
Wherein the eclipta prostrata is called eclipta alba, is cold in nature, sour in taste and sweet in taste, belongs to kidney channels and liver channels, and has the basic effects of tonifying kidney, cooling blood, nourishing liver and stopping bleeding; herba Artemisiae Anomalae, also known as LIUYUEXUE, is slightly warm in nature, bitter and pungent in taste, belongs to spleen channel, heart channel and liver channel, and has basic effects of removing blood stasis, dredging channels, resolving food stagnation, relieving pain, removing blood stasis and promoting digestion; katsumadai seed, named as katsumadai seed, is warm in nature and pungent in taste, belongs to stomach channel and spleen channel, and has the basic effects of invigorating stomach, relieving stuffiness, eliminating dampness and warming middle-jiao; the cluster mallow seeds are cold in nature and sweet in taste, belong to small intestine channel, large intestine channel and bladder channel, and have the basic effects of lubricating the intestines, treating stranguria, promoting diuresis and promoting lactation; cortex Periplocae Radicis, also known as periploca sepium, is slightly warm in nature, bitter and pungent in taste, belongs to heart channel, kidney channel and liver channel, and has the basic effects of eliminating dampness, strengthening tendons, inducing diuresis, dispelling pathogenic wind, relieving swelling and strengthening bones; fiveleaf akebia fruit, cold in nature, sweet in taste and bitter in taste, belongs to kidney, spleen and liver meridians, and has the basic effects of regulating qi, relieving pain, soothing liver and activating blood circulation. In the traditional Chinese medicine composition, the monarch drug Ecliptae herba and the herba Artemisiae Anomalae have basic effects of tonifying kidney and dissipating blood stasis; the ministerial medicines of the katsumadai seed and the malva seed have the basic effects of invigorating the stomach and lubricating the intestines; the cortex Periplocae Radicis is used as adjuvant drug, and has the basic effect of eliminating dampness; the medicated fiveleaf akebia fruit has the basic effect of regulating qi. The compatibility of the medicines can produce the effects of tonifying kidney, dissipating blood stasis, invigorating stomach, moistening intestines, eliminating dampness and regulating qi.
Preferably, the traditional Chinese medicine composition consists of the following raw material medicines in parts by weight: 12.5 parts of eclipta prostrata, 6 parts of artemisia anomala, 4 parts of alpinia katsumadai, 10 parts of cluster mallow seeds, 4.5 parts of cortex periplocae and 12 parts of fiveleaf akebia fruit.
The experimental result of the behavioral tests shows that compared with a drug-free control group, the incubation period of the Kunming mouse in the model verification group is obviously prolonged (P is less than 0.05), and the incubation period of the Kunming mouse in the simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the incubation period of Kunming mice in western medicine intervention group, traditional Chinese medicine composition high dose group and traditional Chinese medicine composition medium dose group is obviously shortened (P is less than 0.05), the incubation period of Kunming mice in traditional Chinese medicine composition low dose group is not obviously changed (P is more than 0.05), and the results show that the learning and memory ability of beta-amyloid induced Alzheimer disease cleaning-grade Kunming mouse model can be improved by traditional Chinese medicine composition high dose (12.74g/kg) and traditional Chinese medicine composition medium dose (6.37 g/kg).
The enzyme-linked immunosorbent assay result shows that compared with a drug-free control group, the beta-amyloid precursor protein content (P is less than 0.05) and the interleukin-1 beta content (P is less than 0.05) of a Kunming mouse in a model verification group are obviously increased, and the beta-amyloid precursor protein content and the interleukin-1 beta content of the Kunming mouse in a simulated operation group are not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine pretreatment group, the traditional Chinese medicine composition high-dose group and the traditional Chinese medicine composition medium-dose group have the advantages that the beta-amyloid precursor protein content and the interleukin-1 beta content of the Kunming mouse are obviously reduced (P is less than 0.05), the beta-amyloid precursor protein content and the interleukin-1 beta content of the Kunming mouse are not obviously changed (P is more than 0.05) in the composition low-dose group, the high-dose (12.74g/kg) and the medium-dose (6.37g/kg) of the traditional Chinese medicine composition can improve the beta-amyloid precursor protein content and the interleukin-1 beta content of the Kunming mouse model with the beta-amyloid induced Alzheimer disease clean grade, and the high-dose (12.74g/kg) and the medium-dose (6.37g/kg) of the traditional Chinese medicine composition can improve the inflammatory medium level and the inflammatory medium level of the Kunming mouse model with the beta-amyloid induced Alzheimer disease clean grade It reduces senile plaque deposition, which is associated with a reduction in the level of microglial and astrocyte activation.
The immunohistochemistry and gene detection results show that compared with a drug-free control group, the model verification group has the advantages that the acetylcholine metabolic enzyme protein and gene expression quantity of Kunming mice are obviously increased (P is less than 0.05), the choline acetylase protein and gene expression quantity are obviously reduced (P is less than 0.05), and the acetylcholine metabolic enzyme protein and gene expression quantity of Kunming mice in a simulated operation group are not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the traditional Chinese medicine composition high dose group, the traditional Chinese medicine composition medium dose group are that the acetylcholine metabolic enzyme protein and the gene expression quantity of Kunming mice are obviously reduced (P is less than 0.05), the choline acetylase protein and the gene expression quantity are obviously increased (P is less than 0.05), the composition low dose group is that the acetylcholine metabolic enzyme, the choline acetylase protein and the gene expression quantity of Kunming mice are not obviously changed (P is more than 0.05), and the body brain tissue choline acetylase is proved, the abnormal expression of the acetylcholine metabolic enzyme of the brain tissue of the body can cause the abnormal content of the acetylcholine of the brain tissue of the body, intervene the expression of the choline acetylase of the brain tissue of the body and the acetylcholine metabolic enzyme of the brain tissue of the body, and contribute to improving the Alzheimer disease induced by the beta-amyloid protein by the high dose (12.74g/kg) of the traditional Chinese medicine composition and the dose (6.37g/kg) of the traditional Chinese medicine composition.
The evaluation of the side effect of the traditional Chinese medicine composition on improving the Alzheimer disease induced by the beta-amyloid is related to the evaluation of body weight and organ index. The results show that the index and the body weight of the important organs of Kunming mice in the model verification group and the simulated operation group are not obviously changed compared with the drug-free control group. After treatment with high dose (12.74g/kg) of the traditional Chinese medicine composition, medium dose (6.37g/kg) of the traditional Chinese medicine composition and low dose (3.19g/kg) of the traditional Chinese medicine composition, index and body weight of important organs of Kunming mice in each group are not obviously changed, which indicates that the high dose (12.74g/kg) of the traditional Chinese medicine composition, the medium dose (6.37g/kg) of the traditional Chinese medicine composition and the low dose (3.19g/kg) of the traditional Chinese medicine composition for treating beta-amyloid protein-induced Alzheimer disease clean-grade Kunming mice have no side effect.
In conclusion, the traditional Chinese medicine composition consisting of 6 raw medicinal materials of the ink can effectively treat the beta-amyloid induced Alzheimer disease without side effect.
Furthermore, the invention also provides application of the traditional Chinese medicine composition in preparing a medicine for preventing and treating Alzheimer disease.
Preferably, the Alzheimer's disease is induced by amyloid beta.
Furthermore, the invention also provides a method for preparing the traditional Chinese medicine composition, which comprises the following steps:
(1) weighing the raw materials according to the weight parts, uniformly mixing the raw materials, adding distilled water with the weight of 20-30 times of that of the raw materials, soaking for 2.5-3.5h, decocting for 2.5-3.5h, and cooling;
(2) filtering the liquid medicine cooled in the step (1) by using gauze to obtain a first filtrate;
(3) repeating the steps (1) and (2) to obtain a second filtrate from the residual drug residues in the step (2), and combining the second filtrate;
(4) mixing the first filtrate and the second filtrate, and baking in a drying oven at 60-70 deg.C for 6-8 days to obtain dry extract of Chinese medicinal composition;
(5) pulverizing the obtained dry extract in a pulverizer to obtain dry powder of the Chinese medicinal composition.
Preferably, the filtering with gauze in the step (2) is filtering with 3 layers of gauze, 5 layers of gauze, 8 layers of gauze and 10 layers of gauze in sequence.
Furthermore, the invention also provides a clinically suitable traditional Chinese medicine preparation for treating the Alzheimer disease, which is prepared by adding auxiliary materials required by preparation forming into the traditional Chinese medicine composition according to a conventional method for preparing a medicine preparation.
Wherein, the preparation is preferably powder, decoction, capsules, pills, granules, tablets or oral liquid.
Compared with the prior art, the invention has the beneficial effects that:
the invention discloses a traditional Chinese medicine composition for treating Alzheimer disease, in particular to a beta-amyloid induced Alzheimer disease and a preparation method and application thereof. The basic composition of the traditional Chinese medicine composition comprises 6 traditional Chinese medicines, namely precocious pubescent holly root, diverse wormwood herb, katsumade galangal seed, cluster mallow seed, Chinese silkvine bark and fiveleaf akebia fruit. The traditional Chinese medicine composition has the basic effects of tonifying kidney, dissipating blood stasis, invigorating stomach, moistening intestines, eliminating dampness and regulating qi. Animal experiment results show that the high dose (12.74g/kg) and the medium dose (6.37g/kg) of the traditional Chinese medicine composition can improve the learning ability, the beta-amyloid precursor protein expression level, the interleukin-1 beta expression level and the acetylcholine metabolic enzyme expression level of a Kunming mouse with the beta-amyloid induced Alzheimer disease, and meanwhile, the traditional Chinese medicine composition has no influence on the main organ index and the body weight of the Kunming mouse with the beta-amyloid induced Alzheimer disease, so that the traditional Chinese medicine composition is effective in treating the Alzheimer disease and has no side effect.
Drawings
FIG. 1 is a graph showing the effect of a Chinese medicinal composition on learning ability of Kunming mice induced by beta-amyloid;
note: the abscissa is the group; the ordinate is the latency(s);
FIG. 2 is a graph showing the effect of a Chinese medicinal composition on the content of beta-amyloid precursor protein in Kunming mouse with beta-amyloid-induced Alzheimer's disease;
note: the abscissa is the group; the ordinate is β -amyloid precursor protein (ng/L);
FIG. 3 is a graph showing the effect of a Chinese medicinal composition on the IL-1 β content in beta-amyloid-induced Alzheimer's disease Kunming mice;
note: the abscissa is the group; the ordinate is interleukin-1 β (pg/mL);
FIG. 4 is a graph showing the effect of a Chinese medicinal composition on the content of choline acetylase in Kunming mice with Alzheimer's disease induced by beta-amyloid;
note: the abscissa is the group; the ordinate is choline acetylase (mean optical density value);
FIG. 5 shows the effect of a Chinese medicinal composition on β -amyloid induced acetylcholine metabolizing enzyme in Kunming mice with Alzheimer's disease;
note: the abscissa is the group; the ordinate is the acetylcholine metabolizing enzyme (mean optical density value);
FIG. 6 shows the effect of a Chinese medicinal composition on β -amyloid induced Alzheimer's disease cholinesterase gene in Kunming mice;
note: the abscissa is the group; the ordinate represents choline acetylase (gene expression level);
FIG. 7 shows the effect of a Chinese medicinal composition on the acetylcholine metabolizing enzyme gene of Kunming mice induced by beta-amyloid;
note: the abscissa is the group; the ordinate represents acetylcholine metabolizing enzyme (gene expression level);
FIG. 8 shows the effect of the Chinese medicinal composition on the heart index and lung index of Kunming mice with beta-amyloid induced Alzheimer disease;
note: the abscissa is the group; the ordinate is the heart index, lung index (mg/g);
FIG. 9 shows the effect of the Chinese medicinal composition on kidney index and liver index of Kunming mouse with beta-amyloid induced Alzheimer disease;
note: the abscissa is the group; the ordinate is the renal index, hepatic index (mg/g);
FIG. 10 is a graph of the effect of a Chinese medicinal composition on body weight of beta-amyloid-induced Alzheimer's disease Kunming mice;
note: the abscissa is the group; the ordinate is the weight (g) of Kunming mice at 0, 14, 28 days.
Detailed Description
The present invention is further described below, and the embodiments described in the present description are only exemplary and do not limit the scope of the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention.
Example 1 preparation of a Chinese medicinal composition for the prevention and treatment of Alzheimer's disease
The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 12.5g of eclipta prostrata, 6g of diverse wormwood herb, 4g of alpinia katsumadai, 10g of cluster mallow seed, 4.5g of cortex periplocae and 12g of fiveleaf akebia fruit.
Example 2 preparation of a Chinese medicinal composition for the prevention and treatment of Alzheimer's disease
The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 10g of eclipta prostrata, 8g of artemisia anomala, 3g of alpinia katsumadai, 8g of cluster mallow seeds, 6g of cortex periplocae and 15g of fiveleaf akebia fruit.
Example 3 preparation of a Chinese medicinal composition for the prevention and treatment of Alzheimer's disease
The traditional Chinese medicine composition is prepared from the following raw material medicines by weight: 15g of eclipta prostrata, 5g of artemisia anomala, 5g of katsumade galangal seed, 15g of cluster mallow seed, 4g of cortex periplocae and 10g of fiveleaf akebia fruit.
Example 4 preparation of a Chinese medicinal composition (Dry powder) for the prevention and treatment of Alzheimer's disease
(1) 12.5g of eclipta prostrata, 6g of diverse wormwood herb, 4g of alpinia katsumadai, 10g of cluster mallow seed, 4.5g of cortex periplocae and 12g of fiveleaf akebia fruit, wherein 5 parts are required to be purchased for each part of 49g, and the total amount is 245 g.
(2) 245g of a traditional Chinese medicine composition of precocious pubescent holly root, diverse wormwood herb, alpinia katsumadai, cluster mallow fruit, cortex periplocae and fiveleaf akebia fruit is placed into a 20000mL round-bottomed flask (6000 mL of distilled water) to be soaked for 3 hours, then the mixture is decocted for 3 hours, and then is filtered by 3 layers of gauze, 5 layers of gauze, 8 layers of gauze and 10 layers of gauze to obtain a first filtrate.
(3) Soaking the medicinal residue in 20000mL round-bottom flask (6000 mL distilled water) with large capacity for 3 hr, decocting for 3 hr, filtering with 3 layers of gauze, 5 layers of gauze, 8 layers of gauze, and 10 layers of gauze to obtain second filtrate.
(4) Mixing the first filtrate and the second filtrate, and baking in a drying oven (65 deg.C) for 7 days to obtain 68.35g of Chinese medicinal dry extract.
(5) The dry paste 68.35g of the traditional Chinese medicine composition is put into a pulverizer to be pulverized to obtain 65.24g of dry powder of the traditional Chinese medicine composition.
(6) Separately packaging 65.24g of Chinese medicinal composition dry powder, 10g each bag, and 5.24g the last bag. And (4) preserving in a refrigerator at the temperature of minus 80 ℃.
Example 5 use of the Chinese medicinal composition of the present invention for treating Alzheimer's disease
1 materials of the experiment
1.1 laboratory animals and instruments thereof
56 Kunming mice (SCXK (Jing) 2012-0001), weight (19.6857 +/-0.6887) g, clean grade, male, Beijing Wittingli Hua company, were bred in the center of the university of Chinese medicine, Heilongjiang, by routine. Incubator, Shanghai Wujiu, model BC-J160S; electronic balance, Qingdao Jingcheng corporation, model JC-TP; brain stereotaxic apparatus, hebei huiyan company, model ZH-C; water maze, huai bei zheng hua corporation, model MWM 101; color analysis system, wuhan thousand screen company, model number HMIAS; centrifuge, Shanghai' an kiosk, model TGL-16G, other instruments are offered by Zhang Yingbo auxiliary professor.
1.2 Experimental drugs and reagents thereof
12.5g of eclipta prostrata, 6g of artemisia anomala, 4g of alpinia katsumadai, 10g of chinaberry fruit, 4.5g of cortex periplocae and 12g of fiveleaf akebia fruit, which are purchased from the first subsidiary hospital of the university of Heilongjiang traditional Chinese medicine, 12.5g of eclipta prostrata, 6g of artemisia anomala, 4g of alpinia katsumadai, 10g of cluster malva fruit, 4.5g of cortex periplocae and 12g of fiveleaf akebia fruit are identified by Tianming, and 12.5g of eclipta prostrata, 6g of artemisia anomala, 4g of alpinia katsumadai, 10g of cluster mallow fruit, 4.5g of cortex periplocae and 12g of fiveleaf akebia fruit can be used in a compatibility. Donepezil hydrochloride tablets, wei material pharmaceuticals; beta-amyloid precursor protein, interleukin-1 beta kit, Nanjing institute of technology; acetylcholine metabolizing enzyme, choline acetylase, Santa corporation, usa; other agents are provided by the assistant professor Zhang Yingbo.
2 method of experiment
2.1 grouping of Experimental animals and preparation of models
56 Kunming mice are randomly divided into 8 groups, namely a drug-free control group, a simulated operation group, a model verification group, a western medicine intervention group, a composition low-dose group, a composition medium-dose group and a composition high-dose group. Using amyloid beta1-42 Hippocampus injection and mouse scaring method thereof for preparing model of Alzheimer disease induced by amyloid beta, and performing amyloid beta on model verification group, western medicine intervention group, composition low dose group, composition medium dose group and composition high dose group every morning142 Hippocampus (80 pmol/. mu.L) injections, simulating the surgery group, sterile saline, no intervention in the drug control group, for 20 days. And intervening the model verification group, the western medicine intervention group, the composition low dose group, the composition medium dose group and the composition high dose group by adopting a cat rat scaring method every afternoon, and keeping the control group and the simulation operation group without adopting the cat rat scaring method for 20 days.
2.2 Chinese medicinal composition Dry powder
The same as in example 4.
2.3 calculation of dosing dose and animal dosing
According to the weight ratio of 0.0026: 1, calculating the administration dosage, wherein the traditional Chinese medicine composition comprises 12.5g of eclipta, 6g of diverse wormwood herb, 4g of alpinia katsumadai, 10g of cluster malva seed, 4.5g of cortex periplocae and 12g of fiveleaf akebia fruit, and the total dosage is 49g, the administration dosage of the traditional Chinese medicine composition is 49g, 0.0026 g, 50 g, 6.37g/kg, the middle dosage of the traditional Chinese medicine composition is 6.37g/kg, the high dosage of the traditional Chinese medicine composition is 12.74g/kg, and the low dosage of the traditional Chinese medicine composition is 3.19 g/kg. The dose of donepezil administered is 0.001 g/kg. The control group, the simulated operation group and the model verification group are not dosed with the same amount of physiological saline for intragastric administration; the western medicine intervention group is administrated with 0.001g/kg of donepezil for intragastric administration; the composition is administered to the low-dose group at 3.19g/kg for intragastric administration; the dosage group in the composition is administered with 6.37g/kg for intragastric administration; the composition high dose group was administered 12.74g/kg for intragastric gavage. The duration of administration was 28 days.
2.4 assessment of learning Capacity of animals
The learning ability of each group of Kunming mice is evaluated by using a water maze, the head of the Kunming mice is colored by ink, the internal and external reference objects of the water maze are always kept consistent, training time for maintaining 4 days is carried out in quadrants I, II and III of the water maze, the incubation period of each group of Kunming mice is calculated every time for 60 seconds and 5 days, and the learning ability of animals is evaluated.
2.5 evaluation of the expression levels of beta-amyloid precursor protein and Interleukin-1 beta
After the learning ability of each group of Kunming mice is evaluated by the water maze, the Kunming mice are grabbed, the whole brains are obtained under sterile conditions, the hippocampus is stripped, homogenate is centrifuged, the supernatant is taken, and the absorbance value (OD) is analyzed at the wavelength of 450nm by using an enzyme-linked immunosorbent assay, so that the expression levels of beta-amyloid precursor protein and interleukin-1 beta are further evaluated.
2.6 evaluation of acetylcholine metabolizing enzyme, Choline acetylase protein levels
The experimental personnel wear gloves, water maze is used for evaluating the learning ability of each group of Kunming mice, then the Kunming mice are grabbed, after the heart of the Kunming mice is perfused with 90mL of normal saline, 4% paraformaldehyde is perfused at a constant speed for about 50mL, and after the treatment of conventional paraffin section, the contents of acetylcholine metabolic enzyme and choline acetyltransferase are measured according to the basic method of the kit.
2.7 evaluation of acetylcholine metabolizing enzyme, Choline acetylase Gene levels
After an experimenter wears gloves and water maze evaluates learning ability of each group of Kunming mice, the Kunming mice are grabbed, whole brains and hippocampus thereof are taken, acetylcholine metabolizing enzyme and choline acetylase mRNA are extracted and are reversely transcribed into cDNA, primers aiming at the acetylcholine metabolizing enzyme and the choline acetylase are designed, reaction parameters aiming at the acetylcholine metabolizing enzyme and the choline acetylase are set, and the reaction parameters comprise reaction at 50 ℃ for 2min, reaction at 95 ℃ for 10min, reaction at 95 ℃ for 15s, reaction at 60 ℃ for 1min and manager 42 basic cycles, and the expression levels of the acetylcholine metabolizing enzyme and the choline acetylase genes are measured by using an instrument.
2.8 evaluation of organ index and body weight
After the learning capacity of each group of Kunming mice is evaluated by the water maze, the Kunming mice are grabbed, the weight of each group of Kunming mice is weighed for 0 day, 14 days and 28 days, the Kunming mice are killed after the head is broken, the heart, the lung, the kidney and the liver of the Kunming mice are obtained, and the liver index, the kidney index, the heart index and the lung index are calculated according to a formula. Calculating formulas of the liver index, the kidney index, the heart index and the lung index: organ indexes (mg/g) of heart, lung, kidney and liver are organ mass (mg) of heart, lung, kidney and liver/weight (g) of Kunming mouse.
2.9 statistical analysis of data
The data (expressed by x +/-s) related to the experiment are analyzed by SPSS19.0 software, and the data among the groups are compared by one-factor analysis of variance.
3 results of the experiment
3.1 Effect of Chinese medicinal composition on learning ability of Kunming mouse with Alzheimer's disease induced by beta-amyloid
The experimental result shows that compared with a drug-free control group, the incubation period of the Kunming mouse in the model verification group is obviously prolonged (P is less than 0.05), and the incubation period of the Kunming mouse in the simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the incubation period of Kunming mice in western medicine intervention group, composition high dose group and composition medium dose group is obviously shortened (P is less than 0.05), and the incubation period of Kunming mice in composition low dose group is not obviously changed (P is more than 0.05). See table 1. See fig. 1.
TABLE 1 influence of Chinese medicinal composition on learning ability of Kunming mouse induced by beta-amyloid protein
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.2 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse beta-amyloid precursor protein
The experimental result shows that compared with a drug-free control group, the model verifies that the beta-amyloid precursor protein content of the Kunming mouse in the group is obviously increased (P is less than 0.05), and the beta-amyloid precursor protein content of the Kunming mouse in the simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group and the composition medium dose group have obviously reduced beta-amyloid precursor protein content (P is less than 0.05) of Kunming mice, and the composition low dose group has no obvious change of beta-amyloid precursor protein content (P is more than 0.05) of Kunming mice. See table 2. See fig. 2.
TABLE 2 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse beta-amyloid precursor protein content
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.3 Effect of Chinese medicinal composition on IL-1 beta in beta-amyloid induced Alzheimer's disease Kunming mice
The experimental result shows that compared with a drug-free control group, the model verifies that the interleukin-1 beta content of Kunming mice in a group is obviously increased (P is less than 0.05), and the interleukin-1 beta content of Kunming mice in a simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group and the composition medium dose group have obviously reduced interleukin-1 beta content (P is less than 0.05), and the composition low dose group has no obvious change of interleukin-1 beta content (P is more than 0.05). See table 3. See fig. 3.
TABLE 3 Effect of Chinese medicinal composition on IL-1 beta content in beta-amyloid induced Alzheimer's disease Kunming mice
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.4 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse Choline acetylase
The result shows that compared with a drug-free control group, the model verifies that the choline acetyltransferase average optical density value of the Kunming mouse is obviously reduced (P is less than 0.05), and the choline acetyltransferase average optical density value of the Kunming mouse in a simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group and the composition medium dose group have obviously increased average optical density values of choline acetylase of Kunming mice (P is less than 0.05), and the composition low dose group has no obvious change of the average optical density values of choline acetylase of Kunming mice (P is more than 0.05). See table 4. See fig. 4.
TABLE 4 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse Choline acetylase
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.5 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse Acetylcholinesterase
The result shows that compared with the drug-free control group, the model verifies that the mean optical density value of the acetylcholine metabolizing enzyme of the Kunming mouse is obviously increased (P is less than 0.05), and the mean optical density value of the acetylcholine metabolizing enzyme of the Kunming mouse of the simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group and the composition medium dose group have obviously reduced average optical density values of acetylcholine metabolizing enzyme of Kunming mice (P is less than 0.05), and the composition low dose group has no obvious change of the average optical density values of acetylcholine metabolizing enzyme of Kunming mice (P is more than 0.05). See table 5. See fig. 5.
TABLE 5 Effect of Chinese medicinal compositions on beta-amyloid induced Acetylcholine metabolizing enzyme in Alzheimer's disease Kunming mice
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.6 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer disease Kunming mouse Choline acetylase Gene
The result shows that compared with a drug-free control group, the model verifies that the choline acetylase gene expression quantity of the Kunming mouse is obviously reduced (P is less than 0.05), and the choline acetylase gene expression quantity of the Kunming mouse of a simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group and the composition medium dose group have obviously increased choline acetylase gene expression level of Kunming mice (P is less than 0.05), and the composition low dose group has no obvious change of choline acetylase gene expression level of Kunming mice (P is more than 0.05). See table 6. See fig. 6.
TABLE 6 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse Choline acetylase Gene ((
2-ΔΔCtMethod)
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.7 Effect of Chinese medicinal composition on Acetylcholinesterase Gene of Kunming mouse induced by beta-amyloid protein
The result shows that compared with a drug-free control group, the model verifies that the acetylcholine metabolic enzyme gene expression quantity of the Kunming mouse is obviously increased (P is less than 0.05), and the acetylcholine metabolic enzyme gene expression quantity of the Kunming mouse of a simulated operation group is not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group and the composition medium dose group have obviously reduced expression level of acetylcholine metabolic enzyme genes of Kunming mice (P is less than 0.05), and the composition low dose group has no obvious change of the expression level of the acetylcholine metabolic enzyme genes of Kunming mice (P is more than 0.05). See table 7. See fig. 7.
TABLE 7 Effect of Chinese medicinal compositions on beta-amyloid induced Acetylcholine metabolizing enzyme Gene in Alzheimer's disease Kunming mice ((
2-ΔΔCtMethod)
Note: compared with the drug-free control group:#P＜0.05，##p is more than 0.05; comparison with model validation set:*P＜ 0.05，**P＞0.05
3.8 Effect of Chinese medicinal composition on Heart index and Lung index of Kunming mouse with Alzheimer disease induced by beta-amyloid
The result shows that compared with a drug-free control group, the heart index and the lung index of the Kunming mouse in the model verification group are not obviously changed (P is more than 0.05), and the heart index and the lung index of the Kunming mouse in the simulated operation group are not obviously changed (P is more than 0.05); compared with the model verification group, the western medicine intervention group, the composition high dose group, the composition medium dose group and the composition low dose group have no obvious change of the cardiac index and the pulmonary index of Kunming mice (P is more than 0.05). See table 8. See fig. 8.
TABLE 8 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse Heart index and Lung index: (
n＝8)
Note: compared with the drug-free control group:#p is more than 0.05; comparison with model validation set:*P＞0.05
3.9 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer disease Kunming mouse Kidney index and liver index
The results show that compared with a drug-free control group, the kidney index and the liver index of the Kunming mouse in the model verification group are not obviously changed (P is more than 0.05), and the kidney index and the liver index of the Kunming mouse in the simulated operation group are not obviously changed (P is more than 0.05); compared with the model verification group, the kidney index and the liver index of the Kunming mouse are not obviously changed in the western medicine intervention group, the composition high dose group, the composition middle dose group and the composition low dose group (P is more than 0.05). See table 9. See fig. 9.
TABLE 9 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse Kidney index and liver index: (
n＝8)
Note: compared with the drug-free control group:#p is more than 0.05; comparison with model validation set:*P＞0.05
3.10 Effect of Chinese medicinal composition on beta-amyloid induced Alzheimer's disease Kunming mouse weight
The results show that compared with the control group without drug administration for 0 day, 14 days and 28 days, the body weight of Kunming mice in the model verification group for 0 day, 14 days and 28 days is not obviously changed (P is more than 0.05), and the body weight of Kunming mice in the simulated operation group for 0 day, 14 days and 28 days is not obviously changed (P is more than 0.05); compared with the weight of Kunming mice in 0 day, 14 days and 28 days of the model verification group, the weight of Kunming mice in western medicine intervention group, composition high dose group, composition medium dose group and composition low dose group is not obviously changed (P is more than 0.05). See table 10. See fig. 10.
TABLE 10 Effect of Chinese medicinal compositions on beta-amyloid induced Alzheimer's disease clean-grade Kunming mouse body weight ((R))
n＝8)
Note: compared with the drug-free control group:#p is more than 0.05; comparison with model validation set:*P＞0.05。
Claims (8)
1. the traditional Chinese medicine composition for treating the Alzheimer disease is characterized by comprising the following raw material medicines in parts by weight: 10-15 parts of eclipta prostrata, 3-8 parts of artemisia anomala, 2-6 parts of alpinia katsumadai, 5-15 parts of cluster mallow seeds, 2-6 parts of cortex periplocae and 10-15 parts of fiveleaf akebia fruit.
2. The traditional Chinese medicine composition for treating alzheimer's disease according to claim 1, which is prepared from the following raw materials in parts by weight: 12.5 parts of eclipta prostrata, 6 parts of artemisia anomala, 4 parts of alpinia katsumadai, 10 parts of cluster mallow seeds, 4.5 parts of cortex periplocae and 12 parts of fiveleaf akebia fruit.
3. The use of the Chinese medicinal composition of claim 1 or 2in the preparation of a medicament for the prevention and treatment of alzheimer's disease.
4. The use according to claim 3, wherein said Alzheimer's disease is induced by amyloid-beta.
5. A method of preparing the traditional Chinese medicine composition of claim 1 or 2, characterized by comprising the steps of:
(1) weighing the raw materials according to the parts by weight of the raw materials in the claim 1 or 2, uniformly mixing the raw materials, adding distilled water with the weight of 20-30 times of the weight of the raw materials, soaking for 2.5-3.5h, decocting for 2.5-3.5h, and cooling;
(2) filtering the liquid medicine cooled in the step (1) by using gauze to obtain a first filtrate;
(3) repeating the steps (1) and (2) to obtain a second filtrate from the residual drug residues in the step (2), and combining the second filtrate;
(4) mixing the first filtrate and the second filtrate, and baking in a drying oven at 60-70 deg.C for 6-8 days to obtain dry extract of Chinese medicinal composition;
(5) pulverizing the obtained dry extract in a pulverizer to obtain dry powder of the Chinese medicinal composition.
6. The method of claim 5, wherein the gauze filtration in step (2) is a 3-layer gauze filtration, a 5-layer gauze filtration, an 8-layer gauze filtration, and a 10-layer gauze filtration, in that order.
7. A clinically suitable traditional Chinese medicine preparation for treating Alzheimer disease is characterized in that the traditional Chinese medicine composition of claim 1 or 2 is added with auxiliary materials required by preparation forming and prepared according to a conventional method for preparing a medicine preparation.
8. The Chinese medicinal preparation according to claim 5, wherein the preparation is in the form of powder, decoction, capsule, pill, granule, tablet or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210042538.3A CN114306543B (en) | 2022-01-14 | 2022-01-14 | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210042538.3A CN114306543B (en) | 2022-01-14 | 2022-01-14 | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114306543A true CN114306543A (en) | 2022-04-12 |
| CN114306543B CN114306543B (en) | 2023-04-21 |
Family
ID=81027091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210042538.3A Active CN114306543B (en) | 2022-01-14 | 2022-01-14 | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114306543B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638854A (en) * | 2019-11-01 | 2020-01-03 | 杨浚 | Medicine or health food for preventing and/or treating Alzheimer's disease by thymus gland pathway |
| CN113080382A (en) * | 2021-03-31 | 2021-07-09 | 南京师范大学 | Application of cardamomin serving as acrolein inhibitor |
-
2022
- 2022-01-14 CN CN202210042538.3A patent/CN114306543B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110638854A (en) * | 2019-11-01 | 2020-01-03 | 杨浚 | Medicine or health food for preventing and/or treating Alzheimer's disease by thymus gland pathway |
| CN113080382A (en) * | 2021-03-31 | 2021-07-09 | 南京师范大学 | Application of cardamomin serving as acrolein inhibitor |
Non-Patent Citations (3)
| Title |
|---|
| 未小明: "旱莲草对AD模型大鼠认知功能及炎症介导因子的影响", 《社区医学杂志》 * |
| 王爱梅等: "旱莲草对老年痴呆模型大鼠学习记忆能力的影响及机制", 《中国老年学杂志》 * |
| 石景洋等: "治疗老年痴呆病中药应用频次及临床分析", 《中国实验方剂学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114306543B (en) | 2023-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
| CN109925402B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN111789917A (en) | Traditional Chinese medicine composition for improving intestinal microenvironment of patients with autism spectrum disorder and preparation method and application thereof | |
| CN107106624A (en) | Prevention, the composition for the mixed extract containing mulberries and fuling peel for improving or treating degenerative neural disease | |
| CN109700973B (en) | Traditional Chinese medicine composition for promoting regeneration of hippocampal neuronal cells | |
| CN110201073B (en) | Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN113413439B (en) | Traditional Chinese medicine formula for treating Alzheimer's disease and preparation method of compound preparation of traditional Chinese medicine formula | |
| CN103191175B (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN114306543A (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof | |
| CN1768838A (en) | Chinese medicine preparation for promoting lead-removal and its preparation process | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator | |
| CN111494545A (en) | A Chinese medicinal composition for treating senile dementia, and its preparation method | |
| CN111110733A (en) | Traditional Chinese medicine composition for treating senile gouty arthritis and preparation method and application thereof | |
| CN101244154B (en) | Pharmaceutical combination for bearing and rearing better children, preventing birth defect and improving anamnesis | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| KR20000002474A (en) | Preventive and therapeutic agent for degenerative cerebrum neurological disease | |
| CN108272917A (en) | A kind of Uygur medicine composition and preparation method thereof for treating failure of memory | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN112807383A (en) | Compound lucid ganoderma composition for improving senile dementia and preparation method thereof | |
| CN116549522B (en) | Application of traditional Chinese medicine composition in gout | |
| CN102138982B (en) | Compound valeriana amurensis composition for treating senile dementia, and preparation method and application thereof | |
| CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
| CN117323369A (en) | Traditional Chinese medicine composition for treating Alzheimer disease as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |